In neurorehabilitation and neuromodulation, inducing a temporary positive shift in brain state is relatively straightforward. For instance, Hermann et al. demonstrated that prefrontal transcranial direct current stimulation (tDCS) can "nudge" patients with disorders of consciousness into higher behavioral recovery states. Similarly, Moucheboeuf et al. showed that combining robot-assisted gait training with conventional physiotherapy yields immediate improvements in walking speed and balance for stroke survivors.
Yet, a fundamental question remains: why do these immediate gains so often fade after the intervention ends? This discrepancy defines the challenge of therapeutic durability. As Xiaohua Zhang et al. observed when comparing tDCS and Functional Electrical Stimulation (FES), functional improvements documented during active treatment sessions frequently diminish months later. The brain or body returns to its baseline, treating the therapy as a transient perturbation rather than a permanent reorganization.
State Modulation vs. Structural Plasticity
To understand why therapies lack long-term durability, we must look at the underlying neurobiological mechanisms. Many interventions operate by modulating immediate physiological states. For example, Hui-Yan Niu et al. showed that butylphthalide can stabilize the hypothalamus-pituitary-adrenal (HPA) axis during acute stroke recovery, and Zhenyu Zhang et al. found that 40 Hz light flicker rapidly alters EEG microstates and network complexity.
However, these acute physiological shifts do not automatically translate into long-term structural stability. Anandabai notes a parallel issue in neonatal care, where short-term respiratory stabilization does not guarantee long-term neurodevelopmental protection.
For an effect to be durable, the intervention must cross a threshold from temporary state modulation to permanent structural plasticity. This includes pathways like the remyelination targeted by Meixi Li et al. or the stable network rewiring sought in chronic insomnia treatments by Tie Li et al.. Without triggering these structural changes, the therapeutic benefit behaves like a stretched rubber band, snapping back to its original shape once the external force is removed.
[Acute Intervention] ──> [State Modulation] ──✕──> [Structural Plasticity] ──> [Durable Recovery]
(Transient) (Remyelination / (Sustained Gains)
Network Rewiring)
Overcoming the Plasticity Threshold
How can researchers force the brain past this plasticity threshold? Current strategies focus on cumulative stimulation and personalized optimization.
First, timing and accumulation matter. Quentin Moreau et al. argue that high-level cognitive modulation requires a sustained, cumulative buildup of stimulation over time; randomized, trial-by-trial stimulation risks washing out the effect before plasticity can take root. This cumulative requirement explains why Zhiqing Tang et al. are systematically testing different dosages of intermittent theta burst stimulation (iTBS) to find the precise threshold where motor recovery shifts from transient to permanent.
Second, the delivery must adapt to the individual. Roi Cohen Kadosh et al. utilized AI-driven Bayesian optimization to personalize home-based neurostimulation, demonstrating that tailoring parameters to individual anatomy and baseline performance maximizes immediate cognitive gains.
However, as Özgür Şimşek demonstrates with transcutaneous vagus nerve stimulation (taVNS), and Yuko Goto demonstrates with deep rTMS for intractable pain, even highly targeted acute effects often dissipate quickly without continuous or strategically spaced maintenance sessions.
The Methodological Challenge of Longitudinal Tracking
Proving that a therapy is durable requires tracking outcomes over months or years, a task plagued by methodological hurdles. In a meta-analysis of robotic gait training, Moucheboeuf et al. identified attrition bias as a major confounding factor that obscures long-term efficacy. When patients drop out of extended studies, evaluating whether functional gains persist becomes statistically fraught.
Furthermore, in progressive neurodegenerative conditions, therapies must contend with an ongoing degenerative undertow. Yu Zheng et al. point out that short-term trials of treatments like Ginkgo Biloba Extract cannot confirm whether therapeutic parity with standard drugs holds over the full course of Alzheimer's disease.
To address this, Yiqi Lin et al. designed the SIMPLE study specifically to move beyond brief cognitive training windows, evaluating whether interventions can genuinely delay the long-term clinical conversion to dementia.
When long-term tracking is successfully executed, the results can be paradigm-shifting. A.K. Percy et al. demonstrated that Trofinetide treatment for Rett syndrome maintains symptom improvement for up to 32 months without hitting an efficacy plateau. This proves that targeted interventions can achieve stable, multi-year durability even in severe neurodevelopmental disorders, provided they are tracked long enough to confirm their persistence.